【目的】 探究消脂茶（由佩兰、荷叶、菊花、决明子、净山楂、麸炒白术、茯苓、太子参、陈皮、炙甘草组成）联合阿 托伐他汀钙片治疗高脂血症痰浊内阻证患者的临床疗效。【方法】 采用回顾性队列研究方法，将 2023年 9月至 2024年 9月在 深圳市宝安区中医院门诊就诊的 200例高脂血症痰浊内阻证患者，按治疗方案的不同分为试验组和对照组，每组各 100例。 对照组给予阿托伐他汀钙片治疗，试验组在对照组的基础上联合消脂茶治疗，疗程为8周。观察2组患者治疗前后中医证候 积分和血脂指标[血清总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）]的变 化情况，评价2组患者的临床疗效和用药安全性。【结果】（1）脱落情况方面，对照组3例因缺少复诊资料而脱落，故实际完 成研究197例，其中，试验组100例，对照组97例。（2）疗效方面，治疗8周后，试验组的总有效率为97.00%（97/100），对照 组为87.63%（85/97），组间比较（χ2 检验），试验组的疗效明显优于对照组（P＜0.05）。（3）中医证候积分方面，治疗后，2组患 者的中医证候积分均较治疗前下降（P＜0.05），且试验组的下降幅度明显优于对照组（P＜0.05）。（4）血脂指标方面，治疗后， 2组患者的 TC、TG、LDL-C水平均较治疗前下降（P＜0.05），HDL-C水平均较治疗前升高（P＜0.05），且试验组对 TC、TG、 LDL-C水平的下降幅度及对HDL-C水平的升高幅度均明显优于对照组（P＜0.05）。（5）安全性方面，治疗过程中，2组患者均 未出现严重不良反应，其中，试验组的不良反应发生率为1.00%（1/100），对照组为2.06%（2/97），组间比较，差异无统计学 意义（P＞0.05）。【结论】 消脂茶联合阿托伐他汀钙片治疗高脂血症痰浊内阻证患者疗效确切，能够有效降低血脂指标，改善 患者临床症状，其疗效优于单纯阿托伐他汀钙片治疗。

Objective To investigate the clinical efficacy of Xiaozhi Tea（composed of Eupatorii Herba， Nelumbinis Folium， Chrysanthemi Flos， Cassiae Semen， Crataegi Fructus， bran-fried Atractylodis Macrocephalae Rhizoma，Poria，Pseudostellariae Radix，Citri Reticulatae Pericarpium，Glycyrrhizae Radix et Rhizoma Praeparata cum Melle） combined with Atorvastatin Calcium Tablets for the treatment of hyperlipidemia patients with turbid phlegm obstruction syndrome. Methods A retrospective cohort study was conducted in 200 hyperlipidemia patients with turbid phlegm obstruction syndrome who visited the outpatient department of Shenzhen Bao’an Traditional Chinese Medicine Hospital Group from September 2023 to September 2024. The patients were equally divided into a trial group and a control group based on the treatment regimen，with 100 cases in each group. The control group received oral use of Atorvastatin Calcium Tablets alone，while the trial group received Xiaozhi Tea in addition to Atorvastatin Calcium Tablets orally， both groups were treated for 8 weeks. Changes in traditional Chinese medicine （TCM） syndrome scores and lipid profiles of total cholesterol（TC）， triglycerides （TG）， high-density lipoprotein cholesterol （HDL-C）， and low-density lipoprotein cholesterol （LDL-C） in the two groups were observed before and after treatment. After treatment，the clinical efficacy and safety of the two groups were evaluated. Results （1） There were 3 patients in the control group dropping out due to lack of follow-up data，leaving 197 patients who eventually completed the study，100 cases in the trial group and 97 cases in the control group.（2） After 8 weeks of treatment，the total effective rate in the trial group was 97.00% （97/100） and that in the control group was 87.63% （85/97）. The intergroup comparison （tested by chi-square test） showed that the trial group showed significantly stronger efficacy than the control group （P＜0.05）.（3） Both groups exhibited significant reductions in TCM syndrome scores after treatment in comparison with those before treatment （P＜0.05），and a more pronounced reduction was presented in the trial group （P＜0.05）.（4） Both groups showed decreased TC，TG，and LDL-C levels（P＜0.05） and increased HDL-C level after treatment in comparison with those before treatment （P＜0.05）. The trial group demonstrated more obvious reduction of TC， TG，LDL-C，and more obvious elevation of HDL-C than the control group （P＜0.05）.（5） In terms of safety，no severe adverse reactions occurred in either group. The incidence of adverse reactions in the trial group was 1.00% （1/100） and that in the control group was 2.06%（2/97），with no statistically significant difference between groups （P＞0.05）. Conclusion Xiaozhi Tea combined with Atorvastatin Calcium Tablets exerts certain efficacy in treating hyperlipidemia with turbid phlegm obstruction syndrome，and is effective on significantly improving lipid profiles and clinical symptoms. The combination therapy demonstrates superior efficacy compared to Atorvastatin Calcium Tablets alone.

R259.892

国家自然科学基金青年科学基金项目（编号：82204998）；深圳市“医疗卫生三名工程”项目（编号：SZZYSM202311014）；深圳 市宝安区区属公立医院高质量发展研究项目（编号：YNXM2024007）